-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132

Benzinga·08/11/2026 10:22:36
Listen to the news
BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $112 to $132.